Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityNo recent work listed

Mengtao Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3498-5034; OpenAlex author ID A5051884745, A5101990628. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 0, last author 14)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 5 papers, 2 trials · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper

Papers 18

  1. Pseudostellaria heterophylla Extract Polysaccharide H-1-2 Suppresses Pancreatic Cancer by Inhibiting Hypoxia-Induced AG2. Last author DOI 10.1016/j.omto.2020.03.007↗
  2. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. Co-author DOI 10.1016/j.ebiom.2019.04.008↗
  3. The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma. Last author DOI 10.1186/s12935-019-0828-8↗
  4. Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. Last author DOI 10.3389/fimmu.2019.02819↗
  5. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Last author DOI 10.1155/2018/2360427↗
  6. High Glucose-Induced ROS Production Stimulates Proliferation of Pancreatic Cancer via Inactivating the JNK Pathway. Last author DOI 10.1155/2018/6917206↗
  7. Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Co-author DOI 10.3892/or.2018.6241↗
  8. Dermokine contributes to epithelial-mesenchymal transition through increased activation of signal transducer and activator of transcription 3 in pancreatic can… Last author DOI 10.1111/cas.13347↗
  9. The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382. Last author DOI 10.1159/000479990↗
  10. HNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway. Last author DOI 10.1186/s12935-016-0368-4↗
  11. Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expre… Last author DOI 10.2147/ott.s136840↗
  12. Integrated analysis of mRNA and miRNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2017.5526↗
  13. Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic c… Co-author DOI 10.2147/ott.s103581↗
  14. Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells. Last author DOI 10.2147/ott.s122653↗
  15. Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase… Last author DOI 10.2147/ott.s91511↗
  16. Solanine induces mitochondria-mediated apoptosis in human pancreatic cancer cells. Last author DOI 10.1155/2014/805926↗
  17. Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo. Last author DOI 10.1371/journal.pone.0087868↗
  18. Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells. Last author DOI 10.3892/or.2014.3476↗

Trials 2

  1. Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors Principal investigator NCT03302403↗
  2. Autologous CARTmeso/19 Against Pancreatic Cancer Principal investigator NCT03497819↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bicheng Chen · 10 shared papers, 2014–2018 · strength 0.65
  2. Hongwei Sun · 7 shared papers, 2014–2020 · strength 0.54
  3. Keqing Shi · 4 shared papers, 2018–2020 · strength 0.39
  4. Yukai Xiang · 5 shared papers, 2017–2019 · strength 0.38
  5. Shengjie Dai · 4 shared papers, 2015–2019 · strength 0.28
  6. Dinglai Yu · 4 shared papers, 2016–2018 · strength 0.27
  7. Bicheng Chen · 3 shared papers, 2015–2019 · strength 0.23
  8. Chaohao Huang · 3 shared papers, 2016–2018 · strength 0.20
  9. Xince Huang · 3 shared papers, 2015–2017 · strength 0.19
  10. Songfu Jiang · 1 shared trial, 2017 · strength 0.17
  11. Kang Yu · 1 shared trial, 2017 · strength 0.17
  12. Jie Zhang · 2 shared papers, 2017–2019 · strength 0.16
  13. Yongheng Bai · 2 shared papers, 2014–2018 · strength 0.13
  14. Zongjing Chen · 2 shared papers, 2014–2017 · strength 0.13
  15. Jingfeng Chen · 2 shared papers, 2014–2016 · strength 0.10
  16. Wanqing Weng · 1 shared paper, 2019 · strength 0.09
  17. Weiguo Huang · 1 shared paper, 2019 · strength 0.09
  18. Yangyang Guo · 1 shared paper, 2019 · strength 0.09
  19. Xing Zhang · 1 shared paper, 2018 · strength 0.09
  20. Monika Posaric Bauden · 1 shared paper, 2019 · strength 0.08
  21. György Marko‐Varga · 1 shared paper, 2019 · strength 0.08
  22. Dingyuan Hu · 1 shared paper, 2019 · strength 0.08
  23. Qimin Zhou · 1 shared paper, 2019 · strength 0.08
  24. Roland E. Andersson · 1 shared paper, 2019 · strength 0.08
  25. Daniel Ansari · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.